FindTrial
Sign In

Comparison of new local hemostatic foam (HemoFoam®)and conventional gauze dressing on hemostasis of vascular access site in hemodialysis patients

Comparison of new local hemostatic foam (HemoFoam®)and conventional gauze dressing on hemostasis of vascular access site in hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180625001
Enrollment
Unknown
Registered
2018-06-25
Start date
2017-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding control after needle extraction in Hemodialysis patients Hemodialysis patients&#44

Interventions

This study will be performed in two separate sessions: only HemoFoam® will be used during the first session&#44
and only conventional gauze dressing in the second session in the hemostasis of the arterial or venous access site. Two nurses will be invited to participate in the research. The purpose and protocol
a questionnaire will be used to record patient&#39
s demographic data&#44
blood pressure&#44
history of diabetes&#44
history of hypertension&#44
cause of end&#45
stage renal disease&#44
and bleeding time in HPs who will be enrolled in the study. The time required for homeostasis will be also measured by a stopwatch (Casio HS&#45
80TW&#45
1DF Stopwatch® Casio&#44
made in Japan). At the end of the hemodialysis session&#44
the blood pressure of the patient will be measured and recorded one&#45
time by a standard procedure before the needles extraction (Diplomat&#44
Sphygmomanometer 1002®&#44
Riester&#44
made in Germany). Then&#44
2.8 cc of blood will be drawn from the venous access site and sent to the laboratory for platelet count&#44
hematocrit&#44

Sponsors

no
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients aged 18 to 70 years, hemodialysis via arteriovenous fistula three times a week, Glasgow Coma Scale 15/15, having at least six months of dialysis history.

Exclusion criteria

Exclusion criteria: unwillingness to participate in the study, a vascular or bleeding disorder (coagulopathy), any type of infection in the body, absence of patients in the next hemodialysis sessions, and patient's death during the study.

Design outcomes

Primary

MeasureTime frame
Time of hemostasis At the end of the hemodialysis session stopwatch—

Secondary

MeasureTime frame
blood pressure At the start of the hemodialysis session Sphygmomanometer—

Countries

Iran

Contacts

Public ContactRouhollah Zarepur

M.D., Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

R_Zarepur@yahoo.com+98.9131524497

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026